ORION OYJ |
Market Closed -
Other stock markets
|
After market 03:56:25 pm | |||
| 35.85 EUR | +1.30% |
|
35.86 | +0.01% |
| 10:15am | Orion Corporation Announces Appointments to Nomination Committee | CI |
| Apr. 25 | Transcript : Orion Oyj, Q1 2024 Earnings Call, Apr 25, 2024 |
| Sales 2024 * | 1.36B 1.45B | Sales 2025 * | 1.45B 1.55B | Capitalization | 4.97B 5.33B |
|---|---|---|---|---|---|
| Net income 2024 * | 238M 255M | Net income 2025 * | 249M 267M | EV / Sales 2024 * | 3.67 x |
| Net Debt 2024 * | 4.12M 4.41M | Net cash position 2025 * | 5.14M 5.51M | EV / Sales 2025 * | 3.43 x |
| P/E ratio 2024 * |
20.9
x | P/E ratio 2025 * |
19.9
x | Employees | 3,632 |
| Yield 2024 * |
4.7% | Yield 2025 * |
4.83% | Free-Float | 88.9% |
More Fundamentals
* Assessed data
More news
Latest transcript on Orion Oyj
More press releases
More news
| 1 day | +1.91% | ||
| 1 week | +11.02% | ||
| Current month | +4.05% | ||
| 1 month | +4.47% | ||
| 3 months | -17.75% | ||
| 6 months | -1.29% | ||
| Current year | -8.40% |
1 week
32.25
36.09
1 month
31.8636.09
Current year
31.8645.29
1 year
31.8646.97
3 years
31.8655.16
5 years
28.1955.16
10 years
21.4458.50
| Managers | Title | Age | Since |
|---|---|---|---|
Liisa Hurme
CEO | Chief Executive Officer | 57 | 98-12-31 |
| Director of Finance/CFO | 63 | 00-12-31 | |
| Chief Operating Officer | - | 15-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 63 | 21-03-24 | |
| Director/Board Member | 61 | 17-03-21 | |
| Director/Board Member | 54 | 22-03-22 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 2.96% | 1,331 M€ | +7.08% | ||
| 2.87% | 460 M€ | +1.81% | ||
| 0.35% | 1,120 M€ | -0.07% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 35.85 | +1.30% | 553 435 |
| 24-04-25 | 35.39 | +6.92% | 804,108 |
| 24-04-24 | 33.1 | -0.06% | 312,458 |
| 24-04-23 | 33.12 | +0.36% | 201,846 |
| 24-04-22 | 33 | +1.85% | 234,335 |
Delayed Quote Nasdaq Helsinki, April 26, 2024 at 08:50 am EDT
More quotes
Orion Oyj is Finland's leading pharmaceutical group. Net sales break down by family products and services as follows:
- generic, OTC and biosimilar drugs (43.4%);
- patented prescription products (41.7%): notably intended for treating dysfunctions of the nervous system, cardiovascular diseases, hormonal and urological treatments;
- animal health products (8.7%);
- pharmaceutical ingredients and outsourcing services (6.2%).
Net sales break down primarily by source of revenue between sales of products (86.9%) and royalties (10.4%).
Net sales are distributed geographically as follows: Finland (28%), Scandinavia (12%), Europe (30.8%), North America (14.7%) and other (14.5%).
Sector
Pharmaceuticals
Calendar
2024-08-08
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
HOLD
Number of Analysts
6
Last Close Price
35.39
EUR
Average target price
39.2
EUR
Spread / Average Target
+10.77%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -8.40% | 5.33B | |
| +24.35% | 653B | |
| +25.38% | 556B | |
| -6.33% | 354B | |
| +19.90% | 331B | |
| +7.95% | 296B | |
| +12.79% | 233B | |
| +5.33% | 201B | |
| -10.02% | 193B | |
| -6.47% | 144B |
- Stock Market
- Equities
- ORNBV Stock
